+91-8668442535

Post-Traumatic Stress Disorder Therapeutics Market By Drug Class (Antidepressants, Anti-Anxiety Drugs, Other Drug Classes, Pipeline Candidate) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Industry Outlook

The global post-traumatic stress disorder therapeutics market is expected to reach 10,679.5 million dollars by 2026, with a CAGR of 4.5% during the forecast period from 2018 to 2026. Antidepressants, including SSRIs (Zoloft and Paxil), are among the first lines of treatment for PTSD. They dominated the global market in 2017 and are projected to retain their dominance during the forecast period. North America dominated the PTSD therapeutics market in 2017, accounting for more than half of the market. Higher awareness about healthcare and treatment among the general population and a better rate of self-reporting are some macro factors contributing to the dominance of North America in the global market. Post-traumatic stress disorder (PTSD) is a vastly prevalent disorder but a rarely recognized syndrome that is characterized by some serious reactions such as fear, helplessness, and horror. According to the Diagnostic and Statistical Manual of Mental Disorders, PTSD is categorized as acute if symptoms occur within three months of the trauma and chronic if symptoms occur between three and six months after the trauma.

Post-traumatic stress disorder is classified as an anxiety disorder, and symptoms of PTSD can develop either immediately following a traumatic event or over the course of time. The symptoms of PTSD comprise abnormal mood swings, avoidance of stressful incidents, and so on. PTSD occurs at any age, irrespective of gender; however, the prevalence of PTSD is higher in women. As reported by PTSD United, an estimated one in every eight women develops PTSD in a lifetime, thus making females twice as likely to develop PTSD as males. The prevalence of PTSD in the United States is 3.5%.

The growing prevalence of post-traumatic stress disorder is the chief factor driving the global post-traumatic stress disorder drug market. An increase in events such as wars, combat, and interpersonal violence has been a major contributor to the growing prevalence of PTSD. Factors such as governments' increasing emphasis on rehabilitation initiatives for treating war veterans have also aided the rise in demand for PTSD therapeutics.

The United States dominated the global PTSD therapeutics market. Moreover, the domicile of prominent players and the swift approval of drugs in the region ensure the dominance of North America. Europe is identified as the second largest market due to the growing patient pool, greater awareness regarding the availability and efficacy of therapeutics, and initiatives from government and non-government organizations to strengthen and develop healthcare infrastructure along with a favorable reimbursement system. The awareness of PTSD is low in the Asia Pacific region compared to North America and Europe due to the lack of diagnosis and criticality of mental disorders in the general population.

Market Synopsis

Antidepressant drugs are leading the post-traumatic stress disorder therapeutics market.

Currently, antidepressants, including SSRIs (Zoloft and Paxil), are among the first lines of treatment for PTSD. They dominated the global market in 2017 and are projected to retain their dominance during the forecast period from 2018 to 2026. Moreover, the prevalence of diseases is rising due to the increasing number of accidents and violence worldwide, and the global PTSD therapeutics market is expected to grow during the forecast period from 2018 to 2026.

Periods of History and Forecast

2016 : historic year.

2017: Base Year

2018-2026: Forecast Period

This comprehensive study offers an analysis of every segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each segment is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

A post-traumatic stress disorder therapeutics market study offers the existing market dynamics along with a quantitative analysis of the global market. The report elucidates the detailed outline of the global post-traumatic stress disorder therapeutics market by classifying the market in terms of drug class and geography. The objective of publishing this extensive research report is to support healthcare professionals and market investors in making strategic initiatives and better conclusions in the post-traumatic stress disorder therapeutics market.

Drug Class Segment (2016-2026; US Dollar Millions)

Antidepressants

  • SSRIs
  • SNRIs
  • MAO Inhibitors
  • Tricyclic Antidepressants

Anti-anxiety Drugs

  • Beta-blockers
  • Benzodiazepines

Other Drug Classification

  • Alpha-1 and Alpha-2 Receptor Antagonists
  • Atypical Antipsychotics
  • Anticonvulsants

Pipeline candidates (qualitative information)

  • SRX 246 (Phase II)
  • BNC 210 (Phase II)
  • Tonmya (Phase II)

Geography Segment (2016-2026; millions of dollars)

North America

  • United States
  • Canada

Europe

  • United Kingdom
  • Germany
  • Rest of Europe

Asia-Pacific (APAC)

  • Japan
  • China
  • Rest of APAC

Latin America (LATAM)

  • Mexico
  • Brazil
  • Rest of LATAM

Middle East and Africa (MEA)

  • GCC
  • Rest of the Middle East and Africa

This comprehensive study further describes the major qualitative market assessment factors, including main market drivers, market trends, and restraints, to help in a better understanding of the global post-traumatic stress disorder therapeutics market. Every market assessment factor, including market drivers, challenges, and opportunities, is widely explained considering the existing market situation. This study fully maps the market players based on their strategies, market initiatives, business strengths, and product offerings. Moreover, the report offers an attractive investment proposal based on the widespread geographical research. The main players profiled in the study include Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., and Apotex, Inc., among others.

Key questions are answered in this report.

  • What are the current market trends in the post-traumatic stress disorder therapeutics market and the most valuable opportunities for the players?
  • How does the regulatory framework affect global as well as regional markets?
  • Which drug class is the most prevalent in the PTSD treatment market?
  • How does the FDA's approval of products affect the global market?
  • What are the trends and market sizes in emerging markets such as Japan, Mexico, and Brazil?
  • Which is the largest and fastest-growing regional market?
  • Which is the largest segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Which is the fastest-growing segment by drug class in the post-traumatic stress disorder therapeutics market?
  • Market assessment in terms of value.
  • analysis of market strategies and competitive landscapes

Frequently Asked Questions:

The market for Post-Traumatic Stress Disorder Therapeutics Market is expected to reach US$ 10,679.5 Bn By 2026.

The Post-Traumatic Stress Disorder Therapeutics Market is expected to see significant CAGR growth over the coming years, at 4.5%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Pfizer, Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co., Ltd., Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc., Bionomics Ltd., Tonix Pharmaceuticals Holding Corp., and Apotex, Inc.are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Apr 2018
Category:  Pharmaceuticals
Report ID:   58727
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support